Treating thrombosis – new analysis showing trends, R&D and revenue forecasts See the future of antithrombotic medicines. For those treatments you can now get new sales predictions, also exploring research and development. You can discover business potentials and assess results, trends, technologies, therapies and opportunities.
Visiongain’s updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You can stay ahead with market data on treating thrombotic disorders, finding the commercial prospects to benefit your research, analyses and influence.
Please read on to explore those drug sales and find what the industry could earn in future.
Forecasts to 2025 and other analyses explain and predict the antithrombotics market Why miss the crucial data that you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.
Our study also shows 84 tables, 69 charts and two interviews with authorities in that field.
There you can assess the future of treatments to prevent blood clotting and dissolve blood clots. And the following sections explain what our new investigation provides.
Forecasting of the world market and its segments – what does the future hold? What are the secrets of the industry's progress? Discover in our report overall world revenue prediction to 2025 for antithrombotic medicines, with discussions.
Also you will find individual revenue forecasts to 2025 for eight therapeutic submarkets at world level:
And you will receive forecasts for these anticoagulant drug classes:
• Direct factor Xa inhibitors • Heparins • Direct thrombin inhibitors • Vitamin K antagonists • Other therapeutics (grouped forecast).
There you can assess the outlook for sales expansion, hearing where you could profit. You will investigate the competition and rising sales. And you can examine the clinical and commercial possibilities.
And you can also find top medicines’ potentials.
Predictions of leading products’ sales How will individual drugs perform to 2025 at world level? Our study forecasts revenues of 14 brands. You can assess products, including these:
There you will find the drugs and years with the highest predicted sales. You can also examine the competitors. So discover what’s happening and understand the challenges, trends, competition and opportunities.
Our work also shows geographical revenue predictions.
National markets – what are the outlooks for revenues? In developed and developing countries, many opportunities for producers and sellers of antithrombotic medicines will occur from 2015 to 2025. See where, how and what’s possible.
Our analyses show you individual revenue forecasts to 2025 for 11 national markets:
• United States (US) • Japan • EU leaders – Germany, France, the UK, Italy and Spain (EU5) • BRIC nations – Brazil, Russia, India and China.
There you can explore the progress, needs and opportunities. What events will change that market? Our work shows you, discussing the trends and demands.
Events affecting developers, producers and sellers of those cardiovascular medicines Our report also explains issues, forces and events affecting the antithrombotics industry and market from 2015, including these:
• Progress and outlooks for preventing and treating thrombosis, pulmonary embolism, stroke, acute coronary syndrome (ACS) and related cardiovascular disorders • Expanding patient populations stimulating demand for those blood regulating medicines • Competition from generics and biosimilars, including discussion of regulatory guidelines for biosimilar low-molecular-weight heparin (LMWH).
And these issues are also discussed, among others:
• Governmental healthcare spending and effects on that market’s performance • R&D in antiplatelet agents, anticoagulants, heparins, vitamin K antagonists, direct thrombin inhibitors, direct factor Xa agents, fibrinolytics and other antithrombotics • Development of antidotes for anticoagulation drugs, and the commercial effects.
There you can investigate what stimulates and restrains the industry and affects its results.
Analysis of companies and potential for rising sales – what revenues are possible? What happens next? Our study predicts the world antithrombotics drugs market will rise to $22.4bn in 2019, with high revenues from 2015 to 2025.
You can also see which organisations hold the most potential:
• Sanofi • Boehringer Ingelheim • Bayer • Johnson & Johnson • Genentech.
And also these firms, among others:
• The Medicines Company • Eli Lilly • Otsuka • Pfizer • Bristol-Myers Squibb.
From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from that applied haematology.
Ways Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 helps
In particular, our new investigation gives you this knowledge:
• Antithrombotic revenues to 2025 at overall world level, and also for 8 submarkets and 14 products – assess the outlook for production, marketing and sales
• Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia – investigate the developed and developing countries for potential revenues
• Prospects for established competitors, rising companies and new entrants – explore the portfolios, results, strategies, R&D and outlooks for success
• Review of R&D by therapy group – investigate the progress in research and development, finding technological and medical potentials
• Interviews with other authorities – discover what experts in the field think, say and do, helping you stay ahead
• Analysis of what stimulates and restrains that industry and market – assess the challenges and strengths, helping you compete and gain advantages.
Information found nowhere else, helping your searches, analyses and plans Our new study gives independent analysis. You will receive competitive intelligence found only in our work, finding where the progress and best commercial prospects exist. You will see what’s possible from 2015.
With that definitive market data you’re less likely to fall behind in knowledge or miss opportunity. And you will find in our report how you could save time and effort, also helping your planning, decisions, authority and knowledge.
Trying our report now lets you discover antithrombotic opportunities and predictions Our new investigation is for everyone analysing medications for thrombosis treatment and prevention. There you can discover the trends, discussions and sales predictions. Avoid missing out in commercial knowledge. So please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the World Market for Antithrombotic Drugs 1.2 Why Should You Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Analysis 1.5 Who Is This Study For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQs) 1.8 Some Associated Reports 1.9 About Visiongain 1.10 Glossary of Abbreviations
2. Blood Clotting: Mechanisms, Disorders and Current Treatments 2.1 Understanding Haemostasis and Coagulation 2.2 What is Thrombosis 2.3 Complications of Thrombosis 2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs 2.3.2 Stroke Results From Blockage of Blood Flow to the Brain 2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart 2.4 Antithrombotic Drug Treatment
3. Antithrombotic Drugs: World Market 2015-2025 3.1 The World Antithrombotic Drug Market in 2013 and 2014 3.2 The World Antithrombotic Drug Market: Overarching Revenue Forecast 2014-2025 3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market 3.3.1 An Increasing Patient Population Drives Market Growth 3.3.2 Intense Competition from Generics Threatens to Restrain the Market 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2019 and 2025 3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025 3.6 Anticoagulant Drugs: Leading the Market from 2014 Onwards 3.6.1 Direct Factor Xa Inhibitors: A Novel Therapeutic Class With Great Potential 3.6.2 Heparins: Second-Leading Anticoagulant Class in 2013 3.6.3 Direct Thrombin Inhibitors Achieved High Growth in 2013 and 2014 3.6.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years 3.7 Antiplatelet Drugs Were the Second-Leading Therapeutic Class in 2014 3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market
4. Leading Products in the Market: Prospects, 2015-2025 4.1 Plavix and Lovenox Remain the Market Leaders in 2012 and 2013, Despite Generic Competition 4.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2019 and 2025 4.3 Which Medicines Will Achieve the Highest Rate of Growth to 2025? 4.4 Plavix Faces Competition from Generics, So What Does the Future Hold? 4.4.1 Branded Competition for Plavix? 4.5 Lovenox: Biosimilar Competition in the EU is Expected 4.6 Xarelto: Leading Antithrombotic of 2014 4.7 Pradaxa’s Continued Growth in 2014 4.8 Activase Leads the Fibrinolytics Market, With Little Competition 4.9 Effient Competes with Brilinta/Brilique as well as Generic Competition for Plavix 4.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid 4.11 Angiomax/Angiox is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa 4.12 Pletal Faces Generic Competition and Restrictions on Use in Europe 4.13 Aggrenox/Asasantin to Face Generic Competition Earlier Than Expected in the US 4.14 Sandoz’s Enoxaparin Sodium: Revenue Forecast 2014-2025 4.15 Fragmin Faces Rivalry from Generic Competition to Lovenox 4.16 Brilinta/Brilique: Investigation Closed in 2014 4.17 Eliquis: Will Late Entry to the Market Affect Uptake? 4.18 Arixtra: Aspen Pharmacare Has Acquired Worldwide Rights from GSK 4.19 New Approvals in the Antithrombotic Drugs Market, 2014 4.19.1 Zontivity: The Newest Approval in Antithrombotics 4.19.2 Lixiana/Savaysa: Expansion into Other Regional Markets
5. Leading National Markets, 2014-2025 5.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2013 and 2014? 5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2019 and 2025 5.3 Which National Markets Will Grow Fastest to 2025? 5.4 The US: Dominating the Antithrombotic Drug Market Through 2014-2025 5.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change? 5.5.1 Germany Leads the EU5 5.5.2 France: Healthcare System Reform Will Inhibit Sales Growth? 5.5.3 UK: Pharmaceutical Price Regulation Scheme 5.5.4 Italy’s Healthcare System - Advantages Conducive to Business 5.5.5 Spain: Reductions in Governmental Healthcare Spending Will Restrict Growth 5.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2015-2025 5.7 Chinese Antithrombotic Drug Market Will Capture Market Share 5.8 Brazilian Antithrombotic Drug Market 2015-2025: Strong Growth as Universal Healthcare Coverage is Expanded 5.9 Indian Antithrombotic Drug Market - Limited by Governmental Healthcare Spending? 5.10 Russian Antithrombotic Drug Market: Limited Healthcare Funding Will Prevent Expansive Growth
6. Antithrombotic Drug Development: R&D Pipeline 6.1 The R&D Pipeline for Antithrombotic Drugs: Overview 6.2 The Antiplatelet Drug R&D Pipeline in 2014 6.2.1 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540 6.2.2 The Medicines Company’s Kangrexel (Cangrelor) Awaits Approval 6.3 The R&D Pipeline for Anticoagulants, 2014 6.3.1 Heparins: Little R&D Activity in 2014 6.3.1.1 Will Development of Momenta’s Adomiparin Continue? 6.3.1.2 The Discontinuation of Semuloparin 6.3.2 The Vitamin K Antagonist Pipeline: One Product in Development in 2014 6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued 6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain 6.3.5 Portola Pharmaceuticals’ Betrixaban 6.3.6 Sanofi Has Apparently Discontinued Development of Otamixaban 6.4 The Fibrinolytics R&D Pipeline, 2014 6.4.1 Lundbeck’s Desmoteplase: Failed to Meet Primary Endpoint in Phase III 6.4.2 Bharat Biotech and ThromboGenics’ THR-100 6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2014 6.5.1 Kyowa Hakko Kirin’s KW-3357: Filed in Japan, 2014 6.5.2 Asahi Kasei Pharma America’s ART 123 6.5.3 Regado Biosciences/Tobira Therapeutics is Developing an Anticoagulation System with an Antidote 6.5.4 Isis Pharmaceuticals’ ISIS-FXI Rx
7. Leading Companies in the Antithrombotic Drug Market 7.1 Leading Antithrombotic Drug Manufacturers in 2014 7.2 Sanofi Leads the Market, but is its Position Under Threat? 7.3 Boehringer Ingelheim Captures Market Share 7.4 Bayer Markets Two Antithrombotic Drugs 7.5 Johnson & Johnson Can Achieve Success with a Limited Product Portfolio 7.6 Genentech Will Retain Market Share 7.7 The Medicines Company’s Position Will be Bolstered by the Launch of its New Drug 7.8 Eli Lilly: Market Position is Dependent on Success of Effient 7.9 Otsuka: A Limited Antithrombotic Drug Portfolio 7.10 Pfizer: A Gradually Increasing Share of the Market 7.11 Bristol-Myers Squibb Had a Dramatic Loss of Market Share in 2013
8. Qualitative Analysis of the Antithrombotic Drugs Market, 2015 8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2015 8.1.1 Thrombotic Disease: Management Rather Than Cure 8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market 8.2 Opportunities and Threats Facing the Market 2015-2025 8.2.1 Rising Disease Prevalence Creates Opportunities in the Market 8.2.2 Further Development of Existing Drugs 8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants 8.2.4 The Threat of Generic Competition 8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do? 8.2.6 High Risk of Investment in New Drug Development 8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe 8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2015-2025 8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness 8.3.2 Technological Advances Encourage the Development of Improved Treatment Options 8.3.3 Economic Factors 8.3.3.1 Cost Cutting in the EU and the US 8.3.3.2 Free Trade within the EU Presents Challenges 8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?
9. Research Interviews 9.1 Interview with Dr Sanjay Bhanot, PhD, Vice President of Clinical Development and Translational Medicine, Isis Pharmaceuticals, Inc. 9.1.1 Isis Pharmaceuticals Antithrombotic Drugs Pipeline 9.1.2 ISIS-FXIRx Phase II Results 9.1.3 Trends in the Antithrombotic Drug Market, 2015-2025 9.2 Interview with Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology, Department of Biochemistry, Universidade Federal de São Paulo, Brazil 9.2.1 Recent Research on a Novel Heparin-Like Compound Derived From Shrimp 9.2.2 Heparin vs. Novel Oral Anticoagulants 9.2.3 Unmet Needs in Brazil and Worldwide 9.2.4 Trends in the Antithrombotic Drug Market
10. Conclusions from Our Study 10.1 The World Market for Antithrombotic Drugs 2015-2025 10.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants 10.2 The Leading National Markets 2015-2025 10.3 Trends in the Industry 10.3.1 The Market Will Recover From Plavix Decline 10.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide 10.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years 10.3.4 High Barriers to Market Entry and a Limited Pipeline – The Implications
List of Tables Table 1.1 Antithrombotic Drugs Market Forecast, 2014-2019 Table 1.2 Antithrombotic Drugs Market Forecast, 2019-2025 Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014 Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2013 and 2014 Table 3.2 Overall World Market for Antithrombotic Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 3.3 The Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025 Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2014-2025 Table 3.5 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2014-2025 Table 3.6 Direct Factor Xa Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 3.7 Heparins: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 3.8 Direct Thrombin Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 3.9 The Warfarin Market: Companies and Year of Introduction Table 3.10 Vitamin K Antagonists: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 3.11 Antiplatelet Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 3.12 Fibrinolytics: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.1 Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2013 and 2014 Table 4.2 Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025 Table 4.3 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025 Table 4.4 Plavix: Key Facts, 2014 Table 4.5 Selected Generic Competitors Approved by the FDA, 2014 Table 4.6 Plavix: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.7 Lovenox: Key Facts, 2014 Table 4.8 Lovenox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.9 Xarelto: Key Facts, 2014 Table 4.10 Xarelto: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.11 Pradaxa: Key Facts, 2014 Table 4.12 Pradaxa: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.13 Activase: Key Facts, 2014 Table 4.14 Activase: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.15 Effient: Key Facts, 2014 Table 4.16 Effient: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.17 Aspirin Cardio: Key Facts, 2014 Table 4.18 Aspirin Cardio: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.19 Angiomax/Angiox: Key Facts, 2014 Table 4.20 Angiomax/Angiox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.21 Pletal: Key Facts, 2014 Table 4.22 Pletal: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.23 Aggrenox/Asasantin: Key Facts, 2014 Table 4.24 Aggrenox/Asasantin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.25 Sandoz’s Enoxaparin Sodium: Key Facts, 2014 Table 4.26 Sandoz’s Enoxaparin Sodium: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.27 Fragmin: Key Facts, 2014 Table 4.28 Fragmin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.29 Brilinta: Key Facts, 2014 Table 4.30 Brilinta: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.31 Eliquis: Key Facts, 2014 Table 4.32 Eliquis: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 4.33 Arixtra: Key Facts, 2014 Table 4.34 Zontivity: Key Facts, 2014 Table 4.35 Lixiana/Savaysa: Key Facts, 2014 Table 5.1 Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2013 and 2014 Table 5.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025 Table 5.3 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025 Table 5.4 The US Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.5 The EU5 Market for Antithrombotic Drugs: National Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2014-2025 Table 5.6 The German Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.7 The French Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.8 The UK Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.9 The Italian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.10 The Spanish Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.11 The Japanese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.12 The Chinese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.13 The Brazilian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.14 The Indian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 5.15 The Russian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025 Table 6.1 Selected Candidates in the Antiplatelet Drug R&D Pipeline, 2014 Table 6.2 Selected Candidates in the Heparins Pipeline, 2014 Table 6.3 Selected Candidates in the Vitamin K Antagonist Pipeline, 2014 Table 6.4 Candidates in the Direct Thrombin Inhibitors Pipeline, 2014 Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2014 Table 6.6 The Fibrinolytics R&D Pipeline, 2014 Table 6.7 Other Antithrombotic Drugs in Development, 2014 Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2013 and 2014 Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2014 Table 7.3 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2014 Table 7.4 Bayer: Antithrombotic Drug Portfolio, 2014 Table 7.5 Johnson & Johnson: Antithrombotic Drug Portfolio, 2014 Table 7.6 Genentech: Antithrombotic Drug Portfolio, 2014 Table 7.7 The Medicines Company: Antithrombotic Drug Portfolio, 2014 Table 7.8 Eli Lilly: Antithrombotic Drug Portfolio, 2014 Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2014 Table 7.10 Pfizer: Antithrombotic Drug Portfolio, 2014 Table 7.11 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2014 Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2015 Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2015-2025 Table 8.3 Social, Technological, Economic and Political Forces Influencing the Antithrombotic Drug Market (STEP Analysis), 2015-2025
List of Figures Figure 2.1 Diagram Depicting the Coagulation Cascade Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2013 Figure 3.2 The Antithrombotic Drug Market by Therapeutic Class: Market Share (%), 2014 Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2014-2025 Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2015-2025 Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2019 Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2025 Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2014-2025 Figure 3.8 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2014-2025 Figure 3.9 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2014-2025 Figure 3.10 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2015-2025 Figure 3.11 Heparins: Revenue Forecast ($m), 2014-2025 Figure 3.12 The Heparins Market: Drivers and Restraints, 2015-2025 Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2014-2025 Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2015-2025 Figure 3.15 Vitamin K Antagonists: Revenue Forecast ($m), 2014-2025 Figure 3.16 The Vitamin K Antagonist Market: Drivers and Restraints, 2015-2025 Figure 3.17 Antiplatelet Drugs: Revenue Forecast ($m), 2014-2025 Figure 3.18 The Antiplatelet Drug Market: Drivers and Restraints, 2015-2025 Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2014-2025 Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2015-2025 Figure 4.1 The Leading Antithrombotic Drugs: Market Shares (%), 2013 Figure 4.2 The Leading Antithrombotic Drugs: Market Shares (%), 2014 Figure 4.3 The Leading Antithrombotic Drugs: Market Shares (%), 2019 Figure 4.4 The Leading Antithrombotic Drugs: Market Shares (%), 2025 Figure 4.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025 Figure 4.6 Plavix: Revenue Forecast ($m), 2014-2025 Figure 4.7 Lovenox: Revenue Forecast ($m), 2014-2025 Figure 4.8 Xarelto: Revenue Forecast ($m), 2014-2025 Figure 4.9 Pradaxa: Revenue Forecast ($m), 2014-2025 Figure 4.10 Activase: Revenue Forecast ($m), 2014-2025 Figure 4.11 Effient: Revenue Forecast ($m), 2014-2025 Figure 4.12 Aspirin Cardio: Revenue Forecast ($m), 2014-2025 Figure 4.13 Angiomax/Angiox: Revenue Forecast ($m), 2014-2025 Figure 4.14 Pletal: Revenue Forecast ($m), 2014-2025 Figure 4.15 Aggrenox/Asasantin: Revenue Forecast ($m), 2014-2025 Figure 4.16 Sandoz’s Enoxaparin Sodium: Revenue Forecast ($m), 2014-2025 Figure 4.17 Fragmin: Revenue Forecast ($m), 2014-2025 Figure 4.18 Brilinta: Revenue Forecast ($m), 2014-2025 Figure 4.19 Eliquis: Revenue Forecast ($m), 2014-2025 Figure 5.1 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2013 Figure 5.2 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2014 Figure 5.3 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2019 Figure 5.4 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2025 Figure 5.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025 Figure 5.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2015-2025 Figure 5.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025 Figure 5.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2015-2025 Figure 5.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2015-2025 Figure 5.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2015-2025 Figure 5.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025 Figure 5.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025 Figure 5.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025 Figure 5.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025 Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2014 Figure 7.1 The Top 10 Companies: Market Shares (%), 2013 Figure 7.2 The Top 10 Companies: Market Shares (%), 2014 Figure 10.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m), 2013-2025 Figure 10.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m), 2014, 2019 and 2025
Abbott Laboratories Ablynx Aché Accord Healthcare Actavis Totowa AdvanceCor GmbH Alchemia Amneal Pharms Amphastar Pharmaceuticals Apotex App Pharmaceuticals ARCA biopharma Armetheon ARYx Therapeutics Asahi Kasei Pharma America Aspen Astellas Pharma AstraZeneca Aurobindo Pharma Barr Laboratories (subsidiary of Barr Pharmaceuticals) Barr Pharmaceuticals (now a part of Teva Pharmaceuticals) Bayer Baylor College of Medicine, Houston, Texas Bharat Biotech BioVascular Boehringer Ingelheim Bristol-Myers Squibb Capital TEN II Canyon Pharmaceuticals Committee on Medicinal Products for Human Use (CHMP) CSL Behring Daiichi Sankyo Dexa Medica Diakron Pharmaceuticals Dr. Reddy’s Laboratories DuPont Merck Eisai Eli Lilly EMS Endo Laboratories ESP Pharma Eurofarma European Medicines Agency (EMA) Food and Drug Administration (US FDA) Fournier Pharma Gate Pharmaceuticals Genentech German Institute for Quality and Efficiency in Health Care (IQWiG) GlaxoSmithKline (GSK) Grifols Therapeutics Hercules Bioventures Partners Hoechst Marion Roussell Hospira Hypermarcas Indonesia University Invagen Pharms IPCA Labs Isis Pharmaceuticals Johns Hopkins Medicine Johnson & Johnson (J&J) Judicial Panel on Multidistrict Litigation (US) Kowa Kyowa Hakko Kirin Lee’s Pharmaceutical LG Life Sciences LIMES Institute Lundbeck Macleods Pharmaceuticals Merck & Co. Mitsubishi Mitsubishi Tanabe Pharma Momenta Pharmaceuticals Mutual Pharmaceuticals Mylan Pharmaceuticals National Health Service (NHS) National Institute for Health and Care Excellence (NICE) Novartis Nuvelo Organon Otsuka Pharmaceutical Company Pfizer Pharmaceutical and Medical Devices Agency (PMDA) Pharmacia PLIVA PLx Pharma Portola Pharmaceuticals Pozen Regado Biosciences Roche Roxane Laboratories Sandoz Sanofi ScieGen Pharmaceuticals Sun Pharmaceuticals Indusdtries Takeda Taro Teva Pharmaceutical Industries The Medicines Company ThromboGenics Tianjin Medical Tobira Therapeutics Torrent Pharmaceuticals Tufts Medical Center Unified Health System (SUS) Universidade Federal de São Paulo University General Hospital University of Insubria (Italy) Upjohn AB US Department of Justice USL Pharma Virginia Commonwealth University Wockhardt World Health Organization (WHO) Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York Zydus Cadila Zydus Pharmaceuticals (USA) Inc. (US Division of Cadila Healthcare)
Download sample pages
Complete the form below to download your free sample pages for Antithrombotic Drugs: World Industry and Market Prospects 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Antithrombotic Drugs: World Industry and Market Prospects 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
